hotspot -WSS

hotspot

author：comprehensive 2025-10-02 21:05:23 - browse：648

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Let's speed up science by embracing open access publishing

focus

WSS

Color Health wants to make cancer screenings convenient

FDA's Pazdur wants cancer trials to range beyond China alone

Neuroscience renaissance leads to new crop of psychiatric drugs

BMI, flaws aside, is found to be useful estimate of body fat in youth

Redefining sustainability for the pharmaceutical industry

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

hotspot

hotspot

focus

Apple is now the first public company to be valued at $3 trillion

Ionis drug prevents swelling attacks due to hereditary angioedema

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Cancer drug shortages should be causing more outrage

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ASCO: Palliative care found as helpful given virtually as in person

Malaria cases in Florida and Texas: Here’s what you need to know

Let's speed up science by embracing open access publishing

hotspot

Intellia reports positive results for its CRISPR

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Cholera vaccine supplies dangerously low, outbreaks surging

'Vaccine

Childhood vaccination ad campaign launches in the U.K.

With trial win, GSK could get blood cancer drug back on market

focus

focus

focus

explore